Drug Trial Radar · NCT06339008
A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis (PREPARED-1)
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Apr 26, 2024
Primary completion
Oct 22, 2026
Study completion Oct 2028
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- Apr 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in adult participants with perennial allergic rhinitis. Participants can expect study participation to last up to 29.5 months.
Conditions
- Perennial Allergic Rhinitis (PAR)
Interventions
LY3650150Drug
Administered SC
PlaceboDrug
Administered SC
Standard therapy for INCSDrug
Administered as intranasal spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline (CFBL) in Total Nasal Symptom Score (TNSS) at Week 16Time frame: Baseline, Week 16
Locations
74 sites in 6 countries. Site status is shown where the registry gives one.
Allergy and Asthma Specialists Medical Group
Huntington Beach, California
310 Clinical Research
Inglewood, California
Allergy & Asthma Associates of Southern California dba. Southern California Research
Laguna Niguel, California
Allergy and Asthma
San Diego, California
Asthma and Allergy Associates, PC
Colorado Springs, Colorado
Allergy and Asthma Diagnostic Center
Tallahassee, Florida
University of South Florida
Tampa, Florida
Northwestern University
Chicago, Illinois
Asthma Allergy Center of Chicago
River Forest, Illinois
Bluegrass Allergy Research
Lexington, Kentucky
Respiratory Medicine Research Institute of Michigan, PLC
Ypsilanti, Michigan
Clinical Research Institute
Minneapolis, Minnesota
University of Missouri Hospital
Columbia, Missouri
Allergy and Asthma Consultants
St Louis, Missouri
Asthma and Allergy Center
Bellevue, Nebraska
Circuit Clinical/Hudson-Essex Allergy
Belleville, New Jersey
Circuit Clinical/Mercer Allergy and Pulmonary Associates
Hamilton, New Jersey
Dr. Patrick Perin
Teaneck, New Jersey
Smith Allergy and Asthma
Horseheads, New York
Allergy Partners
Asheville, North Carolina
Bernstein Clinical Research Center, LLC
Cincinnati, Ohio
Northwest Research Center
Portland, Oregon
Allergy and Clinical Immunology Associates
Pittsburgh, Pennsylvania
AARA Research Center
Dallas, Texas
Kerrville Allergy and Asthma Associates
Kerrville, Texas
Allergy, Asthma & Sinus Center
Greenfield, Wisconsin
Hôpital Erasme, Service Pharmacie
Brussels, Belgium
Pneumocare
Erpent, Belgium
UZ Gent
Ghent, Belgium
UZ Leuven, Pharmacy
Leuven, Belgium
Hôpital de la Citadelle
Liège, Belgium
Internal Medicine Building
Beijing, China
Department of Nasal Allergy
Beijing, China
The Third Xiangya Hospital of Central South University
Changsha, China
GCP Pharmacy
Guangzhou, China
Zhejiang People's Hospital
Hangzhou, China
Jingzhou Central Hospital
Jingzhou, China
The First Affiliated Hospital of Nanchang University
Nanchang, China
The Second Affiliated Hospital of Nanchang University
Nanchang, China
People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, China
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.